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ETATE-OF-THE-ART PAPER1491Nebivololhomas Münzel, Tommaso Gori
lthough it has been in clinical use in Europe for almost ten years, nebivolol has only
ecently been introduced in the U.S. market. Like carvedilol, nebivolol belongs to a third-
eneration of -blockers, which possess direct vasodilator properties in addition to their
drenergic blocking characteristics. Nebivolol improves endothelial function by stimulating
ndothelial nitric oxide synthase and via antioxidative properties. Nebivolol has proven
ntihypertensive and anti-ischemic effects as well as beneficial effects on hemodynamics and
rognosis in patients with congestive heart failure. Further studies are warranted to compare
ebivolol with other -blockers, and to determine whether the novel properties of nebivolol
ake it a viable first-line agent for hypertension.CLINICAL RESEARCH NTERVENTIONAL CARDIOLOGY1500Long-Term Results of Unprotected Left Main StentingMACCE Death MI Stroke TLR
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p = 0.037awel E. Buszman, Piotr P. Buszman, R. Stefan Kiesz, Andrzej Bochenek, Blazej Trela,
agda Konkolewska, David Wallace-Bradley, Mirosław Wilczyn´ski, Iwona Banasiewicz-Szkro´bka,
wa Peszek-Przybyla, Marek Krol, Marek Kondys, Krzysztof Milewski, Szymon Wiernek,
arcin De˛bin´ski, Aleksander Z˙urakowski, Jack L. Martin, Michał Tendera
his study by Buszman and colleagues evaluated early and late outcomes in 252 patients after
ercutaneous coronary intevention in unprotected left main coronary arteries (ULMCA) with
ither bare-metal stent (BMS) or drug-eluting stent (DES) use. Major adverse cardiovascular
nd cerebral events (MACCE) occurred in 4.8% of patients during the first 30 days and
ncluded death in 1.5%. After 12 months, angiographically confirmed restenosis occurred in
2%. The 5- and 10-year survival rates were 78% and 69%, respectively. Despite differences
n demographical and clinical data in favor of BMS patients, there was a significantly lower
ACCE rate in DES patients (26% vs. 15%). Stenting of ULMCA is feasible and offers
ood long-term outcome, particularly in patients who receive DES.
ditorial Comment: Jeffrey W. Moses, Martin B. Leon, Gregg W. Stone, p. 1512(continued on page A-29)
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aEART FAILURE1515Mathematical Model May Improve the Diagnosis of AHFrian Steinhart, Kevin E. Thorpe, Ahmed M. Bayoumi Gordon Moe, James L. Januzzi, Jr,
. David Mazer
teinhart and colleagues hypothesized that using N-terminal pro–B-type natruiretic peptide
NT-proBNP) levels as a continuous variable rather than a single cut-point would improve
he accuracy of diagnosis of acute heart failure (AHF). Subjects who presented to an
mergency department (ED) with shortness of breath were divided based on the ED
linician’s assessment of the probability of AHF: low (20%), high (80%), and
ntermediate. The etiology of the shortness of breath was determined by chart review but was
linded to the B-type natriuretic peptide level. Variables used in the model to predict AHF
ere age, pre-test probability and log NT-proBNP. The model appropriately reclassified 44%
f patients with intermediate clinical probability to either low or high probability with
egligible (3%) inappropriate redirection. This diagnostic prediction model for AHF that
tilized both clinical assessment and NT-proBNP has excellent diagnostic accuracy and can
elp reduce the incidence of intermediate probability.ditorial Comment: Kenneth Dickstein, p. 1522IABETIC CARDIOMYOPATHY1524Decreased Myocardial Glucose Uptake and Diastolic Dysfunction in Diabeticsuuk J. Rijzewijk, Rutger W. van der Meer, Hildo J. Lamb, Hugo W. A. M. de Jong,
ark Lubberink, Johannes A. Romijn, Jeroen J. Bax, Albert de Roos, Jos W. Twisk, Robert J. Heine,
driaan A. Lammertsma, Johannes W. A. Smit, Michaela Diamant
ijzewijk and colleagues investigated how myocardial substrate and high-energy phosphate
etabolism affected myocardial function in patients with well-controlled, uncomplicated type
diabetes (T2DM). Subjects with T2DM and healthy controls with no evidence of ischemia
n stress echocardiograms underwent cardiac magnetic resonance imaging to evaluate left
entricular (LV) morphology and function and positron emission tomography imaging to
easure myocardial perfusion and substrate metabolism. In T2DM subjects, LV diastolic
unction and myocardial glucose uptake were decreased, whereas myocardial nonesterified
atty acid uptake and oxidation were increased. There were no differences in myocardial high
nergy phosphate metabolism or perfusion. Patients with uncomplicated T2DM have
mpaired LV diastolic function in the setting of myocardial insulin resistance leading to
ltered myocardial substrate metabolism.(continued on page A-32)
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NARDIAC IMAGING1533Measuring the Costs and Implications of Incidental Findings on Cardiac CTimmy MacHaalany, Yeung Yam, Terrence D. Ruddy, Arun Abraham, Li Chen, Rob S. Beanlands,
enjamin J. W. Chow
acHaalany and colleagues sought to determine the incidence, clinical significance, and
otential financial impact of noncardiac incidental findings (IF) identified with cardiac
omputed tomography (CT). In nearly 1,000 consecutive patients undergoing cardiac CT, the
oncardiac structures were evaluated after full field of view (32 to 50 cm) reconstruction. IF
ere categorized as: clinically significant (CS) (a new or unsuspected diagnosis such as
ulmonary embolism), indeterminate (such as nodules requiring serial evaluation), or clinically
nsignificant. Forty-one percent of patients had noncardiac IF, including CS findings in 1.2%
nd indeterminate findings in 7%. After a median 1.5 years of follow-up, none of the
ndeterminate findings became CS. One patient suffered a major complication related to the
nvestigation of an IF. The total direct cost associated with investigating IF was $57,596.
lthough noncardiac IF are common, they are rarely clinically significant. Investigating IF is
ssociated with increased cost and patient risk.ditorial Comment: Mark A. Hlatky, Carlos Iribarren, p. 1542YEAR IN CARDIOLOGY SERIES EAR IN CARDIOLOGY SERIES1544The Year in Non–ST-Segment Elevation Acute Coronary Syndromeobert P. Giugliano, Eugene Braunwald
uigliano and Braunwald review the literature for pertinent articles related to the treatment
nd prognosis in patients with non–ST-segment elevation acute coronary syndrome (NSTE-
CS). This review ranges from imaging techniques to identify vulnerable plaque, to
reatment options, to measures of compliance with recommended therapies. Well over 100
rticles are referenced, almost all of which were published in the last year, providing a
uccinct, practical reference resource for clinicians regarding the contemporary management of
STE-ACS patients.
